Explore the words cloud of the ProMiDis project. It provides you a very rough idea of what is the project "ProMiDis" about.
The following table provides information about the project.
ETHNIKO IDRYMA EREVNON
|Coordinator Country||Greece [EL]|
|Total cost||1˙972˙000 €|
|EC max contribution||1˙972˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-03-01 to 2024-02-29|
Take a look of project's partnership.
|1||ETHNIKO IDRYMA EREVNON||EL (ATHINA)||coordinator||1˙972˙000.00|
It is now widely recognized that a variety of major diseases, such as Alzheimer’s disease, Huntington’s disease, systemic amyloidosis, cystic fibrosis, type 2 diabetes etc., are characterized by a common molecular origin: the misfolding of specific proteins. These disorders have been termed protein misfolding diseases (PMDs) and the vast majority of them remain incurable. Here, I propose the development of a unified approach for the discovery of potential therapeutics against PMDs. I will generate engineered bacterial cells that function as a broadly applicable discovery platform for compounds that rescue the misfolding of PMD-associated proteins (MisPs). These compounds will be selected from libraries of drug-like molecules biosynthesized in engineered bacteria using a technology that allows the facile production of billions of different test molecules. These libraries will then be screened in the same bacterial cells that produce them and the rare molecules that rescue MisP misfolding effectively will be selected using an ultrahigh-throughput genetic screen. The effect of the selected compounds on MisP folding will then be evaluated by biochemical and biophysical methods, while their ability to inhibit MisP-induced pathogenicity will be tested in appropriate mammalian cell assays and in established animal models of the associated PMD. The molecules that rescue the misfolding of the target MisPs and antagonize their associated pathogenicity both in vitro and in vivo, will become drug candidates against the corresponding diseases. This procedure will be applied for different MisPs to identify potential therapeutics for four major PMDs: Huntington’s disease, cardiotoxic light chain amyloidosis, dialysis-related amyloidosis and retinitis pigmentosa. Successful realization of ProMiDis will provide invaluable therapeutic leads against major diseases and a unified framework for anti-PMD drug discovery.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMIDIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROMIDIS" are provided by the European Opendata Portal: CORDIS opendata.
The Enemy of the Good: Towards a Theory of Moral ProgressRead More
Discovery and Characterization of Hydrogen-Based High-Temperature SuperconductorsRead More
Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin DomainsRead More